Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look for.
Jazz Pharmaceuticals beat analysts’ revenue expectations by 1.5% last quarter, reporting revenues of $1.05 billion, up 8.5% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ EPS estimates.
Is Jazz Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Jazz Pharmaceuticals’s revenue to grow 4.6% year on year to $1.06 billion, in line with the 4.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.81 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Jazz Pharmaceuticals has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Jazz Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Pfizer delivered year-on-year revenue growth of 21.9%, beating analysts’ expectations by 3%, and Eli Lilly reported revenues up 44.7%, in line with consensus estimates. Pfizer’s stock price was unchanged after the resultswhile Eli Lilly was up 4.2%.
Read our full analysis of Pfizer’s results here and Eli Lilly’s results here.
Stocks generally had a good 2024. The Fed fought high inflation and won without sending the economy into a recession, otherwise lovingly known as a soft landing. The US Central Bank is now cutting rates. That, plus the election of Donald Trump in November 2024, sent markets even higher, and while some of the pharmaceuticals stocks have shown solid performance, the group has generally underperformed, with share prices down 5.3% on average over the last month. Jazz Pharmaceuticals is up 9.4% during the same time and is heading into earnings with an average analyst price target of $184.37 (compared to the current share price of $136.06).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
